All In Biotech

Drug Trial Radar · NCT06747936

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combined Administration of AD-2281 and AD-2282 in Patients With Primary Hypercholesterolemia.

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

129

Actual

Start

Feb 3, 2025

Primary completion

May 30, 2025

Study completion May 30, 2025

Sponsor

Lead sponsor
Addpharma Inc.Industry
Sponsor type
Industry
First posted
Dec 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia

Conditions

  • Primary Hypercholesterolemia

Interventions

  • AD-2281Drug

    PO, Once daily, 8weeks

  • AD-2282Drug

    PO, Once daily, 8weeks

  • Placebo of AD-2282Drug

    PO, Once daily, 8weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change rate of LDL-CTime frame: from baseline at 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital

    Seoul, Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.